Aug 18 (Reuters) - AzurRx BioPharma Inc :
* AZURRX BIOPHARMA ANNOUNCES POSITIVE TOPLINE DATA FOR PHASE 2 MS1819 COMBINATION THERAPY TRIAL IN CYSTIC FIBROSIS PATIENTS WITH SEVERE EXOCRINE PANCREATIC INSUFFICIENCY $(EPI)$
* AZURRX BIOPHARMA INC - MS1819 AND PERT COMBINATION THERAPY ACHIEVES PRIMARY AND SECONDARY OUTCOME MEASURE ENDPOINTS
* AZURRX BIOPHARMA INC - STUDY DATA INDICATES CLINICALLY MEANINGFUL IMPROVEMENT IN COEFFICIENT OF FAT ABSORPTION $(CFA)$ PRIMARY ENDPOINT
* AZURRX BIOPHARMA INC - 20-PATIENT STUDY SUGGESTS COMBINATION THERAPY MAY BENEFIT CYSTIC FIBROSIS PATIENTS WITH SEVERE EPI
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.